⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 1, 2015Journal of Clinical OncologyOpen Access

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Karen Kelly Nasser K. Altorki Wilfried Eberhardt Mary O’Brien David R. Spigel Lucio Crinò Chun-Ming Tsai Joo-Hang Kim Eun Kyung Cho Philip C. Hoffman С. В. Орлов Piotr Serwatowski Jiuzhou Wang Margaret A. Foley Julie D. Horan Frances A. Shepherd

View Full Paper

Ask AI

Bookmark

Share

Abstract

Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kelly et al. (2015) studied this question.

synapsesocial.com/papers/69dcc30ed4d0de07d11339bd https://doi.org/10.1200/jco.2015.61.8918

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung CancerMeta-Analysis · 2004 · 2,335 citations
2Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung CancerCohort Study · 2005 · 1,810 citations
3Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsRisk Assessment · 2008 · 973 citations
4Erlotinib in Previously Treated Non–Small-Cell Lung CancerRCT · 2005 · 5,425 citations
5Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeHuman Clinical Trial · 2005 · 1,831 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer2006
Prospective Molecular Marker Analyses of <i>EGFR</i> and <i>KRAS</i> From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer2011
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial1975
KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non–Small Cell Lung CancerJournal of Clinical Oncology · 2026
Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 StudyJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from Cornell University

More from Presbyterian Hospital